NCT05982275View on ClinicalTrials.gov

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Multiple MyelomaAllogeneic Stem Cell Transplantation

Interventions

GENETIC

CARTemis-1

A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).

Trial Locations (5)

37007

Complejo asistencial universitario de Salamanca, Salamanca

39008

Hospital Universitario Marques de Valdecilla, Santander

41011

José Antonio Pérez Simón, Seville

46010

Hospital Clínico de Valencia, Valencia

08025

Hospital Santa Creu i Sant Pau, Barcelona

All Listed Sponsors

lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

NCT05982275 - Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant | Biotech Hunter | Biotech Hunter